• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    ASLAN Pharmaceuticals Appoints Dr Kathleen Metters as Independent Director

    3/18/21 7:27:29 AM ET
    $ASLN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ASLN alert in real time by email

    SINGAPORE, March 18, 2021 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq:ASLN), a clinical-stage immunology focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced the appointment of Kathleen M. Metters, PhD, as an independent director. Dr Metters has more than 30 years’ experience in the discovery and development of novel therapies for the treatment of chronic diseases, including autoimmune diseases. Dr Metters is a member of several boards, including Hemoshear Therapeutics LLC and Pharmaxis Ltd (ASX:PXS). Most recently, she was Chief Executive Officer and President of Lycera Corp, where she spearheaded a robust pipeline of proprietary and partnered immune modulator programs.

    Kathleen spent over 20 years at Merck & Co where she held a number of leadership positions, including Senior Vice President and Head of Worldwide Basic Research, with oversight of all the company’s global research projects, and Senior Vice President, External Discovery and Preclinical Sciences. She was also Chair of the Respiratory Worldwide Business Strategy Team, reporting directly to the Chief Executive Officer. Dr Metters holds a BSc in Biochemistry from the University of Manchester Institute for Science and Technology, and a PhD from Imperial College of Science and Technology in London.

    Damien Lim, representative of BV Healthcare II Pte Ltd, has transitioned off the board with effect from March 18, 2021, after serving for 10 years.

    Andrew Howden, Chairman, ASLAN Pharmaceuticals, said, “We are pleased to welcome Dr Metters to ASLAN’s board of directors and look forward to working with her. Kathleen is an accomplished industry leader who brings extensive scientific acumen and global development expertise in immunology. Her insight and experience, combined with that of Dr Neil Graham who recently joined the board, will provide valuable guidance to the management team as ASLAN advances its clinical programs and its pivot to the US. On behalf of the board, I would like to extend our appreciation to Damien Lim for his significant contributions to the growth of the company over the past decade.”

    Media and IR contacts

    Emma Thompson
    Spurwing Communications
    Tel: +65 6751 2021
    Email: [email protected]
    Robert Uhl
    Westwicke Partners
    Tel: +1 858 356 5932
    Email: [email protected]

    About ASLAN Pharmaceuticals
    ASLAN Pharmaceuticals (Nasdaq:ASLN) is a clinical-stage immunology focused biopharmaceutical company developing innovative treatments to transform the lives of patients. Led by a senior management team with extensive experience in global development and commercialisation, ASLAN has a clinical portfolio comprised of a first-in-class monoclonal therapy, ASLAN004, that is being developed in atopic dermatitis and other immunology indications, and ASLAN003, which it plans to develop for autoimmune disease. For additional information please visit www.aslanpharma.com.


    Get the next $ASLN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ASLN

    DatePrice TargetRatingAnalyst
    7/9/2021$8.00Buy
    Jefferies
    More analyst ratings

    $ASLN
    SEC Filings

    See more
    • SEC Form 25-NSE filed by ASLAN Pharmaceuticals Limited

      25-NSE - ASLAN Pharmaceuticals Ltd (0001722926) (Subject)

      9/6/24 7:41:52 AM ET
      $ASLN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by ASLAN Pharmaceuticals Limited

      SCHEDULE 13G/A - ASLAN Pharmaceuticals Ltd (0001722926) (Subject)

      8/8/24 11:36:38 AM ET
      $ASLN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by ASLAN Pharmaceuticals Limited

      6-K - ASLAN Pharmaceuticals Ltd (0001722926) (Filer)

      7/17/24 7:29:55 AM ET
      $ASLN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ASLN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • ASLAN Pharmaceuticals Announces it Has Filed for Voluntary Liquidation of Its Sole Operating Subsidiary and is Commencing Steps to Place Itself Into Voluntary Liquidation

      Following a thorough review of all strategic alternatives, ASLAN Pharmaceuticals Pte Ltd, the sole operating subsidiary of ASLAN Pharmaceuticals, has filed for voluntary liquidation Quantuma (Singapore) Pte Limited International has been appointed as the official liquidator and will seek potential strategic alternatives for the Company's development programs, eblasakimab and farudodstat SAN MATEO, Calif. and SINGAPORE, July 17, 2024 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals ("ASLAN" or the "Company"), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced that its Singapore-incorporated, sole oper

      7/17/24 7:25:04 AM ET
      $ASLN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ASLAN Pharmaceuticals Announces Receipt of Nasdaq Delisting Determination; Has Determined Not to Appeal

      SAN MATEO, Calif. and SINGAPORE, July 15, 2024 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (("ASLAN" or the "Company", NASDAQ:ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced that on July 9, 2024, the Company was notified by the staff of the Listing Qualifications Department (the "Staff") of The Nasdaq Stock Market LLC ("Nasdaq") that, based upon the Company's non-compliance with the $1.00 bid price and $2.5 million stockholders' equity requirements for continued listing on The Nasdaq Capital Market, as set forth in Nasdaq Listing Rules 5550(a)(2) and 5550(b)(1), respectively, the Staff

      7/15/24 7:30:00 AM ET
      $ASLN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ASLAN Pharmaceuticals Announces Plan to Implement ADS Ratio Change

      SAN MATEO, Calif. and SINGAPORE, June 14, 2024 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (("ASLAN" or the "Company", NASDAQ:ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced that it plans to change the ratio of the American Depositary Shares ("ADSs") to its ordinary shares, par value $0.01 per share, from one (1) ADS representing twenty-five (25) ordinary shares to one (1) ADS representing two hundred (200) ordinary shares. For the Company's existing ADS holders, the change in the ADS ratio will have the same effect as a one-for-eight reverse ADS split. There will be no change to the C

      6/14/24 4:54:19 PM ET
      $ASLN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ASLN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by ASLAN Pharmaceuticals Limited

      SC 13G - ASLAN Pharmaceuticals Ltd (0001722926) (Subject)

      3/21/24 4:42:13 PM ET
      $ASLN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by ASLAN Pharmaceuticals Limited

      SC 13G - ASLAN Pharmaceuticals Ltd (0001722926) (Subject)

      3/19/24 4:30:30 PM ET
      $ASLN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by ASLAN Pharmaceuticals Limited (Amendment)

      SC 13G/A - ASLAN Pharmaceuticals Ltd (0001722926) (Subject)

      2/14/24 4:45:26 PM ET
      $ASLN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ASLN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Jefferies initiated coverage on ASLAN Pharmaceuticals with a new price target

      Jefferies initiated coverage of ASLAN Pharmaceuticals with a rating of Buy and set a new price target of $8.00

      7/9/21 7:45:23 AM ET
      $ASLN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HC Wainwright & Co. reiterated coverage on ASLAN Pharmaceuticals with a new price target

      HC Wainwright & Co. reiterated coverage of ASLAN Pharmaceuticals with a rating of Buy and set a new price target of $8.00 from $5.00 previously

      3/17/21 6:40:11 AM ET
      $ASLN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ASLN
    Financials

    Live finance-specific insights

    See more
    • ASLAN Pharmaceuticals Announces Positive Data Conclusively Establishing Proof of Concept for ASLAN004 in Atopic Dermatitis

      - Topline data from multiple-ascending-dose study supports a potentially differentiated safety and efficacy profile - ASLAN004 achieved a statistically significant improvement (p<0.0251) versus placebo in the primary efficacy endpoint of percent change from baseline in EASI with significant improvements in other efficacy endpoints- Well-tolerated with no cases of conjunctivitis in the expansion cohort- On track to enroll first patient in global Phase 2b study in 4Q 21- Management to host conference call and webcast today, 27 September, at 8am ET / 8pm SGTMENLO PARK, Calif. and SINGAPORE, Sept. 27, 2021 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (NASDAQ:ASLN), a clinical-stage, immunology

      9/27/21 6:00:00 AM ET
      $ASLN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ASLN
    Leadership Updates

    Live Leadership Updates

    See more
    • ASLAN Pharmaceuticals Announces New Translational Data on Eblasakimab in COPD and Appoints Leading Respiratory Experts as Scientific Advisors

      New translational data from a head-to-head study of eblasakimab and dupilumab in a human tissue model of COPD shows eblasakimab performed better than dupilumab in improving airway function and enhancing bronchodilation at the same concentrationsLeading respiratory experts, Ramaswamy Krishnan, PhD, and Reynold Panettieri, MD, appointed as scientific advisors to provide strategic counsel on eblasakimab's differentiation for future clinical development in COPD SAN MATEO, Calif. and SINGAPORE, March 06, 2024 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals Ltd. (NASDAQ:ASLN), a clinical-stage, immunology focused biopharmaceutical company developing innovative treatments to transform the lives of p

      3/6/24 7:00:00 AM ET
      $ASLN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ASLAN Pharmaceuticals Appoints Dermatology Veteran Dr Alex Kaoukhov as Chief Medical Officer

      - Dermatologist with over twenty years of experience in senior biopharma roles in the US and Europe, including positions at Almirall, Allergan and Novartis- Strengthens leadership team as eblasakimab (also known as ASLAN004) moves into late-stage trials MENLO PARK, Calif. and SINGAPORE, March 15, 2022 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (NASDAQ:ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced the appointment of Alex Kaoukhov, MD, as Chief Medical Officer based in ASLAN's US office, effective immediately. Alex was most recently Head of Clinical Development, Senior Vice President

      3/15/22 7:00:00 AM ET
      $ASLN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ASLAN Pharmaceuticals and IQVIA Biotech Enter Into Strategic Collaboration

      MENLO PARK, Calif. and SINGAPORE, Dec. 06, 2021 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (NASDAQ:ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced the appointment of IQVIA Biotech, a leading global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry, as its preferred clinical research organization for logistics related to decentralized clinical trials, including the global oversight, expansion and engagement of patients for trials related to the clinical development of ASLAN004 and ASLAN003. IQVIA Biotech will provide pati

      12/6/21 7:00:00 AM ET
      $ASLN
      $IQV
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Commercial Physical & Biological Resarch